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ORIGINAL ARTICLE
The seroprevalence and salivary shedding of
herpesviruses in Behc¸et’s syndrome and
recurrent aphthous stomatitis
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Background: Behc¸et’s syndrome (BS) is one of the multisystemic diseases that presents with oral ulceration
and several other systemic manifestations including genital ulceration, folliculitis, erythema nodosum-like
lesions, uveitis, and arthropathy. Ocular manifestation, central nervous system involvement, and gastro-
intestinal manifestation account for most of the complications of this disease, whereas orogenital ulceration
and dermatological involvement affects the quality of life. The cause of the disease is not fully elucidated;
however, herpesviruses have long been thought to play a pivotal role in the disease pathogenesis.
Objective: To investigate the seroprevalence and salivary shedding of herpesviruses in BS.
Method: The levels of specific immunoglobulin G in six different herpesviruses in serum samples collected
from 54 BS, 28 healthy controls (HC), and 7 recurrent aphthous stomatitis (RAS) patients were investigated.
Salivary viral load was also quantified for these viruses in matched saliva samples using quantitative real-time
polymerase chain reaction.
Results: The BS had lower cytomegalovirus (CMV) IgG level in comparison to HC (p0.0226) and RAS
(p0.0450). There was statistically significant higher salivary shedding of Epstein-Barr virus (EBV) in BS in
comparison to HC (p0.0052), but not RAS (p0.3318).
Conclusions: A high EBV shedding was observed in both BS and RAS and a lower level of CMV IgG was
observed in BS only. The reason for the observed lower level of CMV IgG in BS is not clear. However, one
explanation might be a defect in the cross-talk between innate and adaptive immune responses which was
suggested by a previously described defect in the toll-like receptor 1 and 2 heterodimer formation and function,
this being the initial receptor sensing of CMV.
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B
ehc¸et’s syndrome (BS) is a multisystemic, immune-
related disease with complex aetiopathogenesis. The
major clinical manifestations of BS are recurrent
oral ulceration affecting 9799% that classically precede
any systemic features (1).
Risk of visual loss reaches 25% after 10 years of the
BS ocular disease. Furthermore, severe central nervous
system and pulmonary involvements, catastrophic bleed-
ing from large vessels, bowel perforation, and complica-
tion of immunosuppressive therapy has been reported (2).
The aetiology of BS has not been completely eluci-
dated. An infectious aetiology was postulated more than
50 years ago by Hulusi Behc¸et who suggested a viral
cause for BS. Later, Denman et al. and then Eglin et al.
have shown by in situ DNADNA hybridisation that at
least part of the herpes simplex type 1 (HSV-1) genome
is transcribed in mononuclear cells of some patients
with BS (35). However, administration of high doses of
acyclovir in association with plasma exchanges failed
to produce positive treatment results and treatment
with acyclovir alone failed to alleviate the frequency and
severity of orogenital ulceration or other BS features in a
randomised, double-blind, placebo-controlled crossover
trial (6).
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In other studies, the level of immunoglobulin G
(IgG) antibody against HSV-1 was found to be signifi-
cantly increased in patients who had BS but there was no
HSV-1 DNA found in peripheral blood leukocytes and
oral smears from the same cohort (7). Also, there was no
statistically significant increase in HSV-1 DNA observed
in the saliva of BS patients in comparison to healthy
controls (HC) (8).
In addition to HSV-1, human cytomegalovirus (CMV)
has been studied in relation to BS. CMV DNA was
detected in biopsy specimens from the oral mucosa of BS
patients (9). In another study, the mean titre of IgG and
IgA antibodies to CMV were found to be significantly
lower in BS patients than in HC. Interestingly, the number
of patients having IgM antibody against CMV was similar
between BS patients and HC (10). These studies examined
BS cohorts from Taiwan and Korea; however, there is no
study investigating the prevalence of CMV infection in BS
patients from Western European countries.
EpsteinBarr virus (EBV) was also suggested as a
potential cause of BS. EBV DNA was observed in the
pre-ulcerative oral ulceration of patients with BS and
recurrent aphthous stomatitis (RAS) in avery small cohort
(four BS, five HC, and nine RAS) (11).
To the best of our knowledge, this study is the first
statistically powered case-control study investigating the
seroprevalence of almost all human herpesviruses in BS
from a Western country. We also investigated the sali-
vary viral shedding in the same cohort of patients. A small
cohort of RAS was also investigated as a disease control as
these patients experience recurrent oral ulceration similar
to BS but they do not experience the other complex sys-
temic manifestation of BS.
Materials and methods
The patient cohort was recruited from the outpatient
departments at the Royal London Hospital and St.
Thomas Hospital after ethical approval and informed
written consent were obtained. Eighty-nine matched serum
and saliva samples were collected from 54 BS (F/M: 35/19,
mean age: 44911), 28 HC (F/M: 15/13, mean age:
34910.5), and 7 RAS (F/M: 4/3, mean age: 49.798).
All BS patients were diagnosed according to the interna-
tional study group criteria (12). Fourteen BS (14/54, 26%)
and two RAS (2/7, 29%) had oral ulcers at the time of
collecting the samples. HC were recruited from the Oral
Medicine clinic in the Royal London Hospital and from
the Queen Mary University staff. RAS were patients
having recurrent oral ulceration without any systemic
manifestation of BS and were also recruited from the
Oral Medicine clinic in the Royal London Hospital.
The specific IgG response to the different herpesviruses
was measured by quantitative immunoassay in the serum
samples. Viral nucleic acid titres in saliva samples were
quantified using quantitative real-time polymerase chain
reaction (qPCR) with specific primers.
Immunoassays
HSV-1 and 2 immunoglobulin G (IgG) ELISA
A 100-ml volume of the 1/100 diluted serum samples
(as recommended by the manufacturers) was added to
enzyme-linked immunosorbent assay (ELISA) plates pre-
coated with either recombinant-gG1 (HSV-1) or gG2
(HSV-2) antigen (Biokit, Barcelona, Spain). The antibo-
dies in the test samples were incubated for 1 h at 378C to
allow binding to the specific antigens. The wells were then
washed to remove unbound material and enzyme-labelled
detection antibodies specific for human IgG (conjugate)
were added and incubated for 30 min at 378C. After
washing to eliminate the unbound material, the enzyme
substrate solution containing a chromogen was added and
incubated for 30 min at room temperature, 20258C. The
reaction was stopped with 100 ml of stop solution and the
colour was read in a spectrophotometer at 620630 nm
reference filters. The intensity of the colour reaction was
directly proportional to the amount of the antibodies in
the specimens.
The samples were tested in duplicate and seven control
samples were tested simultaneously to validate the assay
and extract the quantifiable data. The mean absorbance
of the low positive control was calculated and considered
to be the cut-off value, followed by dividing the sample
absorbance by the cut-off value to obtain a ratio
absorbance/cut-off, which is proportional to the concen-
tration of the HSV-1 and HSV-2 IgG antibodies in each
specimen.
Varicella-zoster virus immunoglobulin G ELISA
Varicella-zoster virus (VZV) IgG was detected and quan-
tified using a similar method to the HSV-1 IgG ELISA.
However, the wells of the VZV IgG ELISA kit were coated
with VZV antigen from partially purified extract of
human fibroblast infected with VZV, strain ELLEN
(ATCC) (Diamedix, FL.). To determine the ELISA
Unit (EU)/ml, the following formula was used following
the manufacturer’s instructions (Absorbance of calibra-
torAbsorbance of sampleEU/ml of sample).
Cytomegalovirus immunoglobulin G ELFA
A CMV IgG was quantified by an automated quantitative
two-step enzyme immunoassay sandwich method with
a final fluorescent detection, enzyme-linked fluorescent
assay (ELFA). All of the assay steps were performed
automatically by Vitek Immuno-Diagnostic Assay System
instrument according to the manufacturer’s instructions
(bioMerieux, Basingstoke, UK). The solid phase recepta-
cle was coated internally by the CMV antigen (strain
AD169) and also acted as pipetting device for the assay.
Fluorescence was measured twice for each sample tested;
the first reading is a background reading of the serum and
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the second one was taken after the incubation period with
the antigen. The calibration curves were stored, auto-
matically calculated, and the results were expressed as
AU/ml. The samples were tested in duplicate, along with
calibrator and control samples to validate the assay.
EpsteinBarr viral capside antigens specific
immunoglobulin G chemiluminiscent immunoassay
EBV viral capside antigens IgG was quantified in the
investigated samples by the LIAISON analyser, following
the manufacturer’s instructions (DiaSorin, Dartford,
UK). The samples were tested in duplicates, along with
calibrator and control samples, to validate the assay. The
fully automated LIAISON immunoassay was used with
its magnetic microparticle technology, chemilumines-
cence with flashlight kinetics, and an isoluminol deriva-
tive as labels. Of each sample, 30 mL were used for this
analysis. All reagents required for the assay (magnetic
particles, luminescence-labelled tracer, two calibrators,
diluent, and assay buffer) were provided ready to use and
assembled in one integrated reagent cartridge identifiable
by a bar-coded label providing information such as lot
number, expiry date, and calibration data. The analyser
automatically calculated the antibody concentrations and
expressed it as U/ml.
Human herpes virus 8 immunoglobulin G indirect
fluorescent assay
An IFA method was used to semi-quantify the HHV-8 IgG
in the serum samples (Advanced Biotechnologies, MD).
The 1:40 diluted serum samples were incubated with HHV-
8-infected cells on a slide, allowing the specific antibody
in the serum sample, if present, to bind with the antigen
expressed on the infected cells, forming an immunological
complex. Incubation was done in a moist chamber for
30 min at 378C. After the wash step (510 min in wash
buffer), the anti-human IgG conjugated to the dye
fluorescein isothiocyanate was added to each well on the
slide and allowed to bind to the antibodyantigen com-
plexes for 30 min at 378C. The slides were then washed
(510 min in wash buffer), mounted, and blindly evaluated
under a fluorescent microscope by two different investi-
gators. Each slide contained 10 tests; positive and negative
controls along with the wash buffer sample were tested
simultaneously with each of the seven patients’ samples to
validate the assay. The positive control was given a semi-
quantitative score equal to 4 and the negative control was
given a score of 0. Each patient sample was scored relative
to the positive and negative controls. The results were
checked for consistency and re-evaluated if there were any
discrepant results between the two investigators.
Validation of the immunoassay
All samples were analysed in duplicate. Negative control,
positive control, and calibrator samples were tested each
time, along with the investigated samples. To validate the
results, the value of these control samples was checked
against the validation range suggested by the manufac-
turer’s instructions.
Nucleic acid purification from saliva samples
Nucleic acid in 300 ml of all saliva samples was simul-
taneously purified along with six water samples as
negative controls. All samples were processed by the
BioRobotMDx workstation using the QIAamp DNA
extraction kit, following the manufacturer’s protocol
(Qiagen, Manchester, UK). This method used the selective
binding properties of a silica-based membrane to purify
DNA samples. Purified DNA samples were then eluted in
10 mM Tris Cl, 0.5 mM EDTA, pH 9 (elution buffer: AE)
and were free from protein, nucleases, and other con-
taminants or inhibitors. All samples were subsequently
spiked with phocine herpesvirus (PHV) DNA to act as
internal control during the qPCR assay.
Real-time polymerase chain reaction
HSV-1, HSV-2, and VZV QPCR
Multiplex real-time amplification of HSV-1, HSV-2,
and VZV DNA using glycoprotein-B-specific primers
was performed (Table 1). The 143 bp, 140 bp, and 97 bp
products were detected in qPCR by the use of TaqMan
probes that are labelled at the 5? end with FAM, JOE, and
Cy5, respectively, and at the 3? end with the appropriate
black hole quenchers (Table 1). The composition of the
qPCR was as follows: 2.5 ml of 1PCR buffer contained
1.5 mmol/L MgCl2 (Qiagen), 5 ml of MgCl2 (25 mmol/L),
7.5 ml of dNTPs (6.25 mmol/L each nucleotides), 1 ml of
the forward and reverse primers (15 pmol/ml), 1 ml of
TaqMan probe (5 pmol/L), and 0.25 ml of HotStarTaq
polymerase (0.25 IU/ml; ABI) made up to a final volume of
20 ml with sterile water (Applied Biosystems, Paisley, UK).
Of extracted DNA, 5 ml was added to each reaction. The
PCR cycling conditions were 2 min at 508C, 10 min at
958C, and 60 cycles of 15 s each at 958C and at 608C. All
samples were analysed in duplicate and the average load
was calculated by using the sequence detection system
software available on the ABI 7700 platform (Applied
Biosystems).
QPCR for CMV and EBV
Quantitative real-time amplification of CMV and EBV
DNA using glycoprotein-B-specific primers was per-
formed (Table 1). The 150 bp product of CMV was
detected in qPCR by using a TaqMan probe which is
labelled at the 5? end with FAM and at the 3? end with the
quencher tetramethylrhodamine (TAMRA). The 96 bp
product of EBV was detected with the TaqMan probe
labelled at the 5? end with JOE and at the 3? end with
BHQ1 (Table 1). The composition of the PCR and cycling
conditions were as in a previously published method (13).
Herpesviruses and BS
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HHV-8 QPCR
Primers, probes for the detection of HHV-8 were chosen
according to the previously published method (14). Probes
were labelled at the 5? and 3? end with FAM and TAMRA,
respectively. TaqMan probes were synthesised with a
3? phosphate group to block extension by Taq poly-
merase (Applied Biosystems) (Table 1). The qPCR condi-
tions were as described above in the CMV/EBV qPCR
experiment.
PHV QPCR and assay validation
Prior to DNA extraction, all clinical samples and nega-
tive control samples were spiked with PHV DNA as an
internal control. Real-time amplification of PHV DNA
using glycoprotein-B-specific primers was performed as
internal control. The 101 bp product was detected in
qPCR by the use of a TaqMan probe which is labelled at
the 5? end with FAM and at the 3? end with the quencher
BHQ1 (Table 1). The composition of the PCR and the
PCR cycling conditions were as described above in the
CMV qPCR experiment. All samples were analysed in
duplicate. They were positive for PHV, which excluded
the presence of PCR inhibitors in the reaction.
Statistical analysis
The statistical power calculation was carried out using
StatMate 2 software (GraphPad, CA) to determine the
minimum number of samples required in each group.
The statistical power calculation was based on previ-
ously published information regarding the seroprevalence
of HSV-1 in London in people aged 30 years or above
(54%) (15).
Mean, median, range, minimum, maximum, standard
deviation (SD), standard error of means (SEM), and
percentage were used in the descriptive statistics. The
seroprevalence of human herpesviruses was measured in
the form of the percentage of positive subjects for the
virus-specific IgG divided by the total number of subjects
studied in each group. The absolute quantity of asympto-
matic herpesvirus shedding in saliva was expressed as
means of the log9SD. The data obtained were analysed
by the MannWhitney U-test when comparing quantita-
tive data from two groups, and non-parametric ANOVA
(KruskalWallis test) when comparing quantitative data
from more than two groups. Differences in the rate were
analysed using Fisher Exact test. The GraphPad Prism†
statistical package was used (GraphPad).
Results
HSV-1 and HSV-2 seroprevalence and salivary
viral load
The HSV-1 IgG level between BS, HC, and RAS showed
no statistical difference (p0.6697). There was also no
Table 1. Primers used in the qPCR for detecting the salivary viral load of HSV-1, HSV-2, VZV, CMV, EBV, HHV-8, and PHV
Target Primers & probes Product size/bp
HSV-1 Fwd TATTGGTGCGATGGCGACAC 143
Rev CTTTCCGCATGTGGGCTCTC
Probe FAM-CCCCGCCCCATACCCTACCCGC-BHQ1
HSV-2 Fwd AGCATCCCGATCACTGTGTACTA 140
Rev GCGATGGTCAGGTTGTACGT
Probe JOE-CAGTGCTGGAACGTGCCTGCCGC-BHQ1
VZV Fwd GCCCGTCTATTCCATTCAGCAA 97
Rev CCCGCAAACTTGTAGAACTGTTG
Probe Cy5-CACACGACGCCTCCGCCGCAG-BHQ3
CMV Fwd GAGGACAACGAAATCCTGTTGGGCA 150
Rev TCGACGGTGGAGATACTGCTGAGG
Probe FAM-CAATCATGCGTTTGAAGAGGTAGTCCACG-BHQ1
EBV Fwd GGCCAGAGGTAAGTGGACTTTAAT 96
Rev GGGGACCCTGAGACGGG
Probe JOE-CCCAACACTCCACCACACCCAGGC-BHQ1
HHV-8 Fwd TCGGTGGCGATGCTTTAGAC 97
Rev TGAAGCAGACGATGCTTTGC
Probe FAM-TCGTAACCCCCGTCTACTTTCCCCG-TAMRA
PHV Fwd CGTTCCAACAACACAACCTACTG 101
Rev CTCTCATATCATCATTCAACTCAGTGT
Probe JOE-ACCACCAATTACTCCTAGTCCACCACCG-BHQ1
HSV, herpes simplex virus; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, EpsteinBarr virus; HHV-8, human herpes virus 8;
PHV, phocine herpesvirus.
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difference in BS patients with or without oral ulcers at
the time of sampling (p0.0779). Mean and SD ex-
pressed as the ratio absorbance/cut-off were as follows:
BS (0.8790.92), HC (0.9690.98), and RAS (0.7590.89).
There was also no statistically significant difference in
the seroprevalence of HSV-1 infection between the three
groups as measured by percentage of positive samples for
HSV-1 IgG, with positivity rate ranges between 46 and
57% (p0.2892) (Table 2). Only one BS patient’s saliva
was positive for HSV-1 by qPCR indicating asympto-
matic shedding of the virus in the saliva.
Similarly, there was no statistically significant differ-
ence in the HSV-2 IgG level between BS, HC, and
RAS (p0.9297). There was also no difference observed
between BS patients with or without oral ulcers at the time
of sampling (p0.2659). Mean and SD expressed as the
ratio absorbance/cut-off were as follows: BS (0.1690.36),
HC (0.1290.22), and RAS (0.2190.45). There was also
no statistically significant difference in the seroprevalence
of HSV-2 infection between BS and HC (p0.2507) and
BS compared to RAS (p0.2507), with positivity rate
ranges between 4 and 14% (Table 2). Salivary HSV-2 viral
load was negative for all patients in each of the three
groups.
VZV seroprevalence and salivary viral load
There were no statistically significant difference in the
VZV IgG level of expression between BS, HC, and RAS
(p0.6054). There was also no difference observed
between BS patients with or without oral ulcers at the
time of sampling (p0.3224). Mean and SD were as
follows: BS (98.66935.1 EU/ml), HC (106.8938.5 EU/
ml), and RAS (91.94950.6 EU/ml). There was also no
statistically significant difference in the seroprevalence of
VZV infection between the three investigated groups, with
positivity rate ranging between 86 and 100% (p0.6978)
(Table 2). Salivary VZV viral load was negative for all
patients in each of the three groups.
CMV IgG level is low in BS
There were statistically significant lower CMV IgG
levels in BS patients’ samples compared to those of
HC (p0.0266) and RAS (p0.0450). There was no dif-
ference observed between BS patients with or without
oral ulcers at the time of sampling (p0.1755). Mean
and SD were as follows: BS (30.67935.2 AU/ml), HC
(48.32937.9 AU/ml), and RAS (55.6946.8 AU/ml) (Fig. 1).
Despite the fact that a lower seropositivity was observed
in BS, there was no statistically significant difference
between the three investigated groups, with the following
positivity rates: BS (50%), HC (64%), and RAS (71%)
(p0.2206) (Table 2). The salivary CMV viral load
was negative for all patients in each of the investigated
groups.
EBV salivary viral load is high in BS
There was no statistically significant difference in the
EBV IgG level of expression between BS, HC, and
RAS (p0.9742). Mean and SD were as follows: BS
(412.39285.0 A/ml), HC (403.29255.5 A/ml), and RAS
(399.49345.8 A/ml). There was also no statistically sig-
nificant difference in the seroprevalence of EBV between
the three groups, with positivity rates ranging between
86 and 96% (p0.1181) (Table 2).
However, there was a significantly higher salivary
shedding of EBV in the saliva of BS compared to HC
(p0.0057). There was no statistically significant differ-
ence between BS and RAS (p0.3318). It was observed
that RAS salivary shedding of EBV was lower than
in BS but higher than in HC. However, there was no
statistically significant difference between RAS and HC in
EBV salivary shedding (p0.4837). Mean and SD of the
absolute shedding of the virus were as follows: BS (2.392.3
log), HC (0.8991.7 log), and RAS (1.492.1 log). There
was also statistically significant higher positivity rate in
BS (55%) compared to HC (25%) (pB0.0001), but not
Table 2. Seroprevalence of herpes virus infections in BS
patients, RAS patients, and HC
BS (n54) RAS (n7) HC (n28)
HSV-1 (29/54) 53.7% (3/7) 42.9% (14/28) 50%
HSV-2 (5/54) 9% (1/7) 14% (1/28) 4%
CMV (27/54) 50% (5/7) 71% (19/28) 64%
EBV (48/54) 89% (6/7) 85.7% (27/28) 96.4%
VZV (54/54) 100% (6/7) 85.7% (28/28) 100%
HHV-8 (14/44) 32% (3/7) 42% (13/27) 48%
CMV, cytomegalovirus; EBV, EpsteinBarr virus; HHV-8, human
herpes virus 8; HSV-1, herpes simplex virus 1; HSV-2, herpes
simplex virus 2; VZV, varicella-zoster virus.
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RAS (43%) (p0.0926). There was statistically significant
higher positivity rate in RAS (43%) in comparison to
HC (25%) (p0.0109) (Fig. 2).
Comparing EBV salivary shedding in BS patients who
had oral ulcers (n14) with BS patients who did not have
oral ulcers at the time of sampling (n40) (p0.135)
showed no statistically significant difference. Mean and
SD of the absolute shedding of the virus were as follows:
BS with oral ulcers (1.892.4 log) and BS without oral
ulcers (2.892.4 log). There was also no statistically sig-
nificant difference in the positivity rate in BS with oral
ulcers (43%) compared to BS without oral ulcers (65%)
(p0.1348).
HHV-8 seroprevalence and salivary viral load
There was no statistically significant difference in HHV-
8 IgG level of expression between BS, HC, and RAS
(p0.3150). The HHV-8 immunoassay used in this study
is a semi-quantitative assay. The six BS patients’ samples
and that of one HC which had high levels of non-specific
binding (identified by the total absence of any negative
cells in the whole slide) were excluded from the analysis
(Fig. 3a). Positive and negative controls are illustrated in
Fig. 3b and c. The prevalence of the HHV-8 is reported
in Table 2. HHV-8 qPCR was negative for all patients in
each of the three investigated groups.
Discussion
There was no statistically significant difference in the
seroprevalence of HSV-1, HSV-2, VZV, and HHV-8 in BS
in comparison to HC and RAS. Moreover, the salivary
viral load of these viruses was negative in the three
investigated groups, apart from only one BS patient who
was positive for HSV-1. These results contradict some of
the earlier studies, especially regarding HSV-1 prevalence
but the validated methodology used in this study along
with the larger cohort substantiate those results (4, 5, 7,
8, 16). In addition, our results are supported by the fact
that BS was not successfully treated by the administration
of high doses of acyclovir in association with plasma
exchanges or treatment with acyclovir alone (6).
There was a statistically significant lower level of de-
tectable CMV specific IgG in the serum samples of BS.
This result is in concordance with the previously published
study by Lee et al. (10). Interestingly, the seroprevalence of
CMV in our BS was only 50%, whereas a much higher
seroprevalence of the CMV infection was reported from
countries along the ‘Silk Route’ reaching 97% in the ages
between 17 and 40 years (17). Initial sensing of CMV
is suggested to be through toll-like receptor (TLR) 1/2
heterodimer (18). Given the known influence of TLR
on the adaptive immune response modulation, it is very
possible (while not the only possible explanation) that
the observed decrease in the CMV IgG is a consequence
of the previous observation of our group regarding
the potential dysfunction of the TLR1/2 heterodimer in
BS (19, 20). Another possible explanation is the lack
of viral exposure; however, one would expect similar
viral exposure between HC and BS who reside in the
same place. Moreover, the BS group showed similar
seroprevalence and specific IgG titre to HC for the other
herpesviruses.
The seroprevalence of EBV in BS was comparable to
that of HC and RAS. However, in concordance with the
results of Sun and colleagues (11), the EBV salivary viral
load of BS was significantly higher compared to HC but
similar to RAS. The dynamic of EBV salivary shedding
was previously studied and variation in the rate of
shedding was observed in the same individual over time
(21). Furthermore, EBV replication was reported in the
salivary glands of other oral diseases such as Sjogren’s
syndrome (22). Systemic infection by microorganisms can
also lead to the reactivation and higher shedding of EBV
(23). Interestingly, the initial sensing of EBV is suggested
to be through TLR2 independent of TLR1 or TLR6 (24).
It is also documented that the released EBV-encoded
dUTPase from infected cells into the extracellular envir-
onment acts as a ligand for TLR2 resulting in the classical
signalling cascade of TLRs activating nuclear factor
kappa B (NFkb) and inducing the production of pro-
inflammatory cytokines such as interleukin 6 (IL6) and
tumour necrosis factor alpha (TNFa) (25). IL6 in turn
supports the latent infection and persistence of EBV
through its potent activation effect on signal transducer
and activator of transcription 3 gene signalling that regu-
late EpsteinBarr nuclear antigen 1 transcription which
plays a crucial role in the maintenance of the EBV epi-
some in infected cells (26). Interestingly, an enhanced
inflammatory reaction is a recognised pathological feature
of BS with a well-recorded, high serum pro-inflammatory
cytokine levels such as TNFa and IL6 (27).
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Fig. 2. The salivary shedding of EBV.
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In conclusion, despite the uncertainty whether the
reported difference in the EBV salivary viral load in BS is
of a causative or reactive nature, it may help unravel some
of the questions in relation to the disease pathogenesis.
Furthermore, the lower levels of CMV IgG may explain
the previously investigated defect in the TLR1/2 hetero-
dimer function that act as the initial receptor sensing
CMV (19).
Key message
1. There was statistically significant low level of
expression of CMV IgG in the serum samples of
BS. As this result is consistent with the findings
of Lee et al. (10), we postulate that this difference
can play an important role in understanding the
complex nature of the pathogenesis of this disease.
2. The defect in the adaptive immune response to
CMV in BS may be explained by the previously
reported defect in the TLR 1/2 heterodimer func-
tion, the initial receptor sensing CMV.
3. The EBV salivary viral load of BS was significantly
higher compared to HC but similar to RAS.
Limitation of the study
The number of samples in the RAS group was small;
however, the study was powered. The statistical power
was calculated based on the seroprevalence of HSV-1 in
London, UK, in people aged 30 years or above (54%)
using the StatMate 2 program (GraphPad).
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Fig. 3. HHV-8 indirect fluorescent assay (IFA). (a) Non-specific binding of HHV-8 infected cells by immunoglobulins in the
serum samples of a BS patient. (b) Positive sample for HHV-8. (c) Negative sample of HHV-8.
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